{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:13:57Z","timestamp":1794716037206,"version":"4.9.1"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"ASD"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.neuropharm.2020.107966","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T19:06:38Z","timestamp":1579028798000},"page":"107966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":478,"special_numbering":"C","title":["Mechanisms of action of currently used antiseizure drugs"],"prefix":"10.1016","volume":"168","author":[{"given":"Graeme J.","family":"Sills","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3296-8193","authenticated-orcid":false,"given":"Michael A.","family":"Rogawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.107966_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-0-12-385952-5.00004-X","article-title":"Pharmacology, signaling and physiological relevance of the G protein-coupled receptor 55","volume":"62","author":"Balenga","year":"2011","journal-title":"Adv. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol."},{"issue":"48","key":"10.1016\/j.neuropharm.2020.107966_bib3","doi-asserted-by":"crossref","first-page":"46020","DOI":"10.1074\/jbc.M207663200","article-title":"Forced subunit assembly in \u03b11\u03b22\u03b32 GABAA receptors. Insight into the absolute arrangement","volume":"277","author":"Baumann","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"35","key":"10.1016\/j.neuropharm.2020.107966_bib4","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.23-35-11158.2003","article-title":"Individual properties of the two functional agonist sites in GABAA receptors","volume":"23","author":"Baumann","year":"2003","journal-title":"J. Neurosci."},{"issue":"41","key":"10.1016\/j.neuropharm.2020.107966_bib5","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1523\/JNEUROSCI.3340-09.2009","article-title":"Extrasynaptic GABAA receptors: form, pharmacology, and function","volume":"29","author":"Belelli","year":"2009","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.expneurol.2010.01.021","article-title":"Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy","volume":"223","author":"Bhaskaran","year":"2010","journal-title":"Exp. Neurol."},{"issue":"12","key":"10.1016\/j.neuropharm.2020.107966_bib7","doi-asserted-by":"crossref","first-page":"e0167965","DOI":"10.1371\/journal.pone.0167965","article-title":"Deletion of Gpr55 results in subtle effects on energy metabolism, motor activity and thermal pain sensation","volume":"11","author":"Bjursell","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0197-0186(95)00158-1","article-title":"GABA transporter heterogeneity: pharmacology and cellular localization","volume":"29","author":"Borden","year":"1996","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0922-4106(94)90089-2","article-title":"Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1","volume":"269","author":"Borden","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.107966_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.pa.33.040193.000545","article-title":"GABAB receptor pharmacology","volume":"33","author":"Bowery","year":"1993","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"25","key":"10.1016\/j.neuropharm.2020.107966_bib199","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1523\/JNEUROSCI.5320-05.2006","article-title":"Chronic valproic acid treatment triggers increased neuropeptide Y expression and signaling in rat nucleus reticularis thalami","volume":"2126","author":"Brill","year":"2006","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs--rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.107966_bib13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40263-017-0463-7","article-title":"The role of GABA receptor agonists in anesthesia and sedation","volume":"31","author":"Brohan","year":"2017","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neuropharm.2007.05.030","article-title":"T-current related effects of antiepileptic drugs and a Ca2+ channel antagonist on thalamic relay and local circuit interneurons in a rat model of absence epilepsy","volume":"53","author":"Broicher","year":"2007","journal-title":"Neuropharmacology"},{"issue":"Pt 8","key":"10.1016\/j.neuropharm.2020.107966_bib15","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/brain\/aws151","article-title":"Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome","volume":"135","author":"Brunklaus","year":"2012","journal-title":"Brain"},{"issue":"20","key":"10.1016\/j.neuropharm.2020.107966_bib16","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1528-1167.2006.00973.x","article-title":"Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam","volume":"48","author":"Carunchio","year":"2007","journal-title":"Epilepsia"},{"issue":"4 Suppl. l","key":"10.1016\/j.neuropharm.2020.107966_bib18","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1152\/physrev.1992.72.suppl_4.S15","article-title":"Cellular and molecular biology of voltage-gated sodium channels","volume":"72","author":"Catterall","year":"1992","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2020.107966_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev.cellbio.16.1.521","article-title":"Structure and regulation of voltage-gated Ca2+ channels","volume":"16","author":"Catterall","year":"2000","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.neuropharm.2020.107966_bib20","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s11064-017-2314-9","article-title":"Forty years of sodium channels: structure, function, pharmacology, and epilepsy","volume":"42","author":"Catterall","year":"2017","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/mol.114.097659","article-title":"Structural basis for pharmacology of voltage-gated sodium and calcium channels","volume":"88","author":"Catterall","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00424-010-0801-9","article-title":"Biophysical characterisation of the persistent sodium current of the Nav1.6 neuronal sodium channel: a single-channel analysis","volume":"460","author":"Chatelier","year":"2010","journal-title":"Pfl\u00fcg. Arch."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/1060028018822124","article-title":"Cannabidiol: a new hope for patients with Dravet or Lennox-Gastaut syndromes","volume":"53","author":"Chen","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.neuropharm.2020.107966_bib25","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.celrep.2018.02.021","article-title":"The \u03b12\u03b4-1-NMDA receptor complex Is critically involved in neuropathic pain development and gabapentin therapeutic actions","volume":"22","author":"Chen","year":"2018","journal-title":"Cell Rep."},{"issue":"27","key":"10.1016\/j.neuropharm.2020.107966_bib26","doi-asserted-by":"crossref","first-page":"19343","DOI":"10.1074\/jbc.M113.479725","article-title":"Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human \u03b11\u03b23\u03b32 \u03b3-aminobutyric acid type A (GABAA) receptor","volume":"288","author":"Chiara","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.bja.2018.02.066","article-title":"Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review","volume":"120","author":"Chincholkar","year":"2018","journal-title":"Br. J. Anaesth."},{"issue":"12","key":"10.1016\/j.neuropharm.2020.107966_bib28","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1440-1681.1995.tb02331.x","article-title":"Molecular and functional diversity of K+ channels","volume":"22","author":"Christie","year":"1995","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"3\u20134","key":"10.1016\/j.neuropharm.2020.107966_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-2999(82)90264-3","article-title":"Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice","volume":"83","author":"Consroe","year":"1982","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/ana.410250610","article-title":"Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons","volume":"25","author":"Coulter","year":"1989","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107966_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev.ph.58.030196.002025","article-title":"Persistent sodium current in mammalian central neurons","volume":"58","author":"Crill","year":"1996","journal-title":"Annu. Rev. Physiol."},{"issue":"26","key":"10.1016\/j.neuropharm.2020.107966_bib32","doi-asserted-by":"crossref","first-page":"15268","DOI":"10.1073\/pnas.96.26.15268","article-title":"Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)","volume":"96","author":"Crowder","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib33","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1460-9568.2004.03625.x","article-title":"Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro","volume":"20","author":"Cunningham","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/14737175.2018.1428562","article-title":"mTOR dysregulation and tuberous sclerosis-related epilepsy","volume":"18","author":"Curatolo","year":"2018","journal-title":"Expert Rev. Neurother."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib35","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1523\/JNEUROSCI.2699-05.2006","article-title":"Synaptic vesicle protein 2 enhances release probability at quiescent synapses","volume":"26","author":"Custer","year":"2006","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00023210-200115050-00001","article-title":"The new generation of GABA enhancers. Potential in the treatment of epilepsy","volume":"15","author":"Czuczwar","year":"2001","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/17425250802677826","article-title":"Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography","volume":"5","author":"Czuczwar","year":"2009","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2020.107966_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0014-2999(97)83041-5","article-title":"Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+","volume":"328","author":"Dailey","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2020.107966_bib39","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","article-title":"Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed","volume":"41","author":"Deckers","year":"2000","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.neuropharm.2020.107966_bib40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14737175.2017.1370375","article-title":"Pharmacological treatment of trigeminal neuralgia","volume":"17","author":"Di Stefano","year":"2017","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0031-6997(24)01394-2","article-title":"The glutamate receptor ion channels","volume":"51","author":"Dingledine","year":"1999","journal-title":"Pharmacol. Rev."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.107966_bib43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrn3311","article-title":"Calcium channel auxiliary \u03b12\u03b4 and \u03b2 subunits: trafficking and one step beyond","volume":"13","author":"Dolphin","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.107966_bib44","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.bbamem.2012.11.019","article-title":"The \u03b12\u03b4 subunits of voltage-gated calcium channels","volume":"1828","author":"Dolphin","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tips.2006.12.006","article-title":"Ca2+ channel \u03b12\u03b4 ligands: novel modulators of neurotransmission","volume":"28","author":"Dooley","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.107.039867","article-title":"The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels","volume":"73","author":"Errington","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrn1625","article-title":"Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors","volume":"6","author":"Farrant","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"31","key":"10.1016\/j.neuropharm.2020.107966_bib48","doi-asserted-by":"crossref","first-page":"23614","DOI":"10.1074\/jbc.M110.122564","article-title":"Barbiturates require the N terminus and first transmembrane domain of the \u03b4 subunit for enhancement of \u03b11\u03b23\u03b4 GABAA receptor currents","volume":"285","author":"Feng","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2020.107966_bib49","first-page":"S115","article-title":"Rational polypharmacy","volume":"36","author":"Ferrendelli","year":"1995","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.neuropharm.2020.107966_bib50","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1523\/JNEUROSCI.13-08-03211.1993","article-title":"Calcium current block by (\u2013)-pentobarbital, phenobarbital, and CHEB but not (+)-pentobarbital in acutely isolated hippocampal CA1 neurons: comparison with effects on GABA-activated Cl\u2013 current","volume":"13","author":"Ffrench-Mullen","year":"1993","journal-title":"J. Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2020.107966_bib51","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1528-1167.2011.03008.x","article-title":"The effects of stiripentol on GABAA receptors","volume":"52","author":"Fisher","year":"2011","journal-title":"Epilepsia"},{"issue":"17","key":"10.1016\/j.neuropharm.2020.107966_bib52","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1523\/JNEUROSCI.5307-13.2014","article-title":"Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesis","volume":"34","author":"Fritsch","year":"2014","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.107966_bib53","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"issue":"43","key":"10.1016\/j.neuropharm.2020.107966_bib54","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1074\/jbc.RA118.004929","article-title":"Inhibitory effects of cannabidiol on voltage-dependent sodium currents","volume":"293","author":"Ghovanloo","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2020.107966_bib55","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","article-title":"Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons","volume":"41","author":"Gibbs","year":"2000","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib56","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1021\/cb500108p","article-title":"Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents","volume":"9","author":"Gilchrist","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2020.107966_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib58","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1152\/jn.00378.2010","article-title":"Mechanisms of sustained high firing rates in two classes of vestibular nucleus neurons: differential contributions of resurgent Na, Kv3, and BK currents","volume":"104","author":"Gittis","year":"2010","journal-title":"J. Neurophysiol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/1871527311312030015","article-title":"Does mechanism of drug action matter to inform rational polytherapy in epilepsy?","volume":"12","author":"Giussani","year":"2013","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib60","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/mol.60.5.1121","article-title":"Block of cloned human T-type calcium channels by succinimide antiepileptic drugs","volume":"60","author":"Gomora","year":"2001","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib61","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0026-895X(25)08760-7","article-title":"Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin","volume":"47","author":"Granger","year":"1995","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib62","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","article-title":"The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy","volume":"53","author":"Gunthorpe","year":"2012","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1124\/pr.57.4.10","article-title":"International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels","volume":"57","author":"Gutman","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2020.107966_bib64","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.neuropharm.2015.04.015","article-title":"Carbonic anhydrase inhibition by acetazolamide reduces in vitro epileptiform synchronization","volume":"95","author":"Hamidi","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.107966_bib65","first-page":"2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","author":"Hansen","year":"2018","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107966_bib66","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/B978-0-444-64076-5.00052-1","article-title":"Tuberous sclerosis complex","volume":"148","author":"Hasbani","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107966_bib67","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide","volume":"89","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.neuropharm.2020.107966_bib68","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1073\/pnas.0708930105","article-title":"Pharmacological disruption of calcium channel trafficking by the \u03b12\u03b3 ligand gabapentin","volume":"105","author":"Hendrich","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.107966_bib69","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02741459","article-title":"The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes","volume":"18","author":"Hevers","year":"1998","journal-title":"Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib72","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","article-title":"Everolimus","volume":"16","author":"Houghton","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neuropharm.2020.107966_bib73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev.ne.17.030194.000335","article-title":"Cloned glutamate receptors","volume":"17","author":"Hollmann","year":"1994","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.107966_bib74","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuropharm.2017.09.018","article-title":"Voltage-gated sodium channel \u03b2 subunits: the power outside the pore in brain development and disease","volume":"132","author":"Hull","year":"2018","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.neuropharm.2020.107966_bib75","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib76","doi-asserted-by":"crossref","first-page":"e0150095","DOI":"10.1371\/journal.pone.0150095","article-title":"Retigabine, a Kv7.2\/Kv7.3-channel opener, attenuates drug-induced seizures in knock-In mice harboring Kcnq2 mutations","volume":"11","author":"Ihara","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib77","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0896-6273(00)81046-6","article-title":"SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release","volume":"24","author":"Janz","year":"1999","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib78","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.118.114975","article-title":"Identifying drugs that bind selectively to intersubunit general anesthetic sites in the \u03b11\u03b23\u03b32 GABAAR transmembrane Domain","volume":"95","author":"Jayakar","year":"2019","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib79","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0883073817696814","article-title":"Targeting the mammalian target of rapamycin for epileptic encephalopathies and malformations of cortical development","volume":"33","author":"Jeong","year":"2018","journal-title":"J. Child Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000268641","article-title":"The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: a patch-clamp study","volume":"85","author":"Jin","year":"2010","journal-title":"Pharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib81","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/mol.116.106401","article-title":"Lacosamide inhibition of Nav1.7 voltage-gated sodium channels: slow binding to fast-inactivated states","volume":"91","author":"Jo","year":"2017","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200822010-00003","article-title":"Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy","volume":"22","author":"Johannessen Landmark","year":"2008","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib83","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","article-title":"Therapeutic landscape for Batten disease: current treatments and future prospects","volume":"15","author":"Johnson","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib84","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib85","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1528-1167.2006.00952.x","article-title":"Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?","volume":"48","author":"Jonker","year":"2007","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib86","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1471-4159.1977.tb10721.x","article-title":"\u03b3-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice","volume":"29","author":"Jung","year":"1977","journal-title":"J. Neurochem."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.107966_bib87","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1528-1167.2009.02089.x","article-title":"Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam","volume":"50","author":"Kaminski","year":"2009","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib88","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neuropharm.2007.11.021","article-title":"SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy","volume":"54","author":"Kaminski","year":"2008","journal-title":"Neuropharmacology"},{"issue":"42","key":"10.1016\/j.neuropharm.2020.107966_bib89","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2011.03.011","article-title":"Antiepileptic drugs in the treatment of psychiatric disorders","volume":"21","author":"Kaufman","year":"2011","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib91","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41556-018-0205-1","article-title":"mTOR as a central hub of nutrient signalling and cell growth","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.107966_bib92","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11064-017-2287-8","article-title":"Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP)","volume":"42","author":"Klein","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2020.107966_bib93","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.yebeh.2013.10.022","article-title":"Role of TRPV1 in susceptibility to PTZ-induced seizure following repeated hyperthermia challenges in neonatal mice","volume":"31","author":"Kong","year":"2014","journal-title":"Epilepsy Behav."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.107966_bib94","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1021\/acs.jcim.8b00347","article-title":"Pushing the limits of computational structure-based drug design with a cryo-EM structure: the Ca2+ channel \u03b12\u03b4-1 subunit as a test case","volume":"58","author":"Kotev","year":"2018","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib95","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised,placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib96","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0920-1211(87)90012-X","article-title":"GABA uptake inhibitors: relevance to antiepileptic drug research","volume":"1","author":"Krogsgaard-Larsen","year":"1987","journal-title":"Epilepsy Res."},{"issue":"19","key":"10.1016\/j.neuropharm.2020.107966_bib97","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1007\/s00018-015-1948-5","article-title":"Structure of potassium channels","volume":"72","author":"Kuang","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib98","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0026-895X(24)13073-8","article-title":"A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels","volume":"54","author":"Kuo","year":"1998","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib99","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0026-895X(25)09804-9","article-title":"Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons","volume":"46","author":"Kuo","year":"1994","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib100","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1124\/mol.51.6.1077","article-title":"Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications","volume":"51","author":"Kuo","year":"1997","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib101","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1212\/WNL.58.3.368","article-title":"Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults","volume":"58","author":"Kuzniecky","year":"2002","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.neuropharm.2020.107966_bib102","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2165\/00003495-200666140-00004","article-title":"Combination therapy in epilepsy: when and what to use","volume":"66","author":"Kwan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2020.107966_bib103","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fnmol.2014.00018","article-title":"Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation","volume":"7","author":"Lasarge","year":"2014","journal-title":"Front. Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0920-1211(97)01034-6","article-title":"Neurochemical actions of gabapentin in mouse brain","volume":"27","author":"Leach","year":"1997","journal-title":"Epilepsy Res."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2020.107966_bib105","article-title":"Neurochemical and behavioral aspects of lamotrigine","volume":"32","author":"Leach","year":"1991","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib106","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00401-005-0017-9","article-title":"GAT1 and GAT3 expression are differently localized in the human epileptogenic hippocampus","volume":"111","author":"Lee","year":"2006","journal-title":"Acta Neuropathol."},{"issue":"Suppl. 7","key":"10.1016\/j.neuropharm.2020.107966_bib107","first-page":"S8","article-title":"Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs","volume":"39","author":"Leeder","year":"1998","journal-title":"Epilepsia"},{"issue":"13","key":"10.1016\/j.neuropharm.2020.107966_bib108","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1523\/JNEUROSCI.18-13-04842.1998","article-title":"On the action of the anti-absence drug ethosuximide in the rat and cat thalamus","volume":"18","author":"Leresche","year":"1998","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib109","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/BF00967253","article-title":"Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain","volume":"18","author":"L\u00f6scher","year":"1993","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-0082(98)00075-6","article-title":"Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action","volume":"58","author":"L\u00f6scher","year":"1999","journal-title":"Prog. Neurobiol."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.107966_bib111","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"L\u00f6scher","year":"2002","journal-title":"CNS Drugs"},{"issue":"Suppl. 8","key":"10.1016\/j.neuropharm.2020.107966_bib112","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12025","article-title":"How theories evolved concerning the mechanism of action of barbiturates","volume":"53","author":"L\u00f6scher","year":"2012","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib113","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0920-1211(94)90012-4","article-title":"Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?","volume":"17","author":"L\u00f6scher","year":"1994","journal-title":"Epilepsy Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib114","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","article-title":"Selective blockade of N-type calcium channels by levetiracetam","volume":"43","author":"Lukyanetz","year":"2002","journal-title":"Epilepsia"},{"issue":"26","key":"10.1016\/j.neuropharm.2020.107966_bib115","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib116","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bbrc.2008.07.145","article-title":"Visualization of SV2A conformations in situ by the use of Protein Tomography","volume":"375","author":"Lynch","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2020.107966_bib117","first-page":"S2","article-title":"Antiepileptic drug mechanisms of action","volume":"36","author":"Macdonald","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.107966_bib118","first-page":"713","article-title":"Anticonvulsant drugs: mechanisms of action","volume":"44","author":"Macdonald","year":"1986","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107966_bib119","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuropharm.2016.01.003","article-title":"Functional sites involved in modulation of the GABAA receptor channel by the intravenous anesthetics propofol, etomidate and pentobarbital","volume":"105","author":"Maldifassi","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.107966_bib120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/B978-0-444-63326-2.00002-8","article-title":"Potassium channel genes and benign familial neonatal epilepsy","volume":"213","author":"Maljevic","year":"2014","journal-title":"Prog. Brain Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib121","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","article-title":"Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders","volume":"9","author":"Mantegazza","year":"2010","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib122","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1528-1157.1987.tb03663.x","article-title":"Adenosine antagonist properties of carbamazepine","volume":"28","author":"Marangos","year":"1987","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib123","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/1570159X14666160729155441","article-title":"Advances in the physiology of GPR55 in the central nervous system","volume":"15","author":"Marichal-Cancino","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2020.107966_bib124","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1146\/annurev.physiol.63.1.815","article-title":"On the cellular and network bases of epileptic seizures","volume":"63","author":"McCormick","year":"2001","journal-title":"Annu. Rev. Physiol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib125","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1528-1167.2011.03392.x","article-title":"Levetiracetam has an activity-dependent effect on inhibitory transmission","volume":"53","author":"Meehan","year":"2012","journal-title":"Epilepsia"},{"issue":"Suppl. 9","key":"10.1016\/j.neuropharm.2020.107966_bib126","first-page":"S2","article-title":"Basic mechanisms of gabitril (tiagabine) and future potential developments","volume":"40","author":"Meldrum","year":"1999","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.neuropharm.2020.107966_bib127","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1111\/ejn.12360","article-title":"Synaptic vesicle protein 2A: basic facts and role in synaptic function","volume":"38","author":"Mendoza-Torreblanca","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.107966_bib128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"Pt A","key":"10.1016\/j.neuropharm.2020.107966_bib129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuropharm.2018.01.036","article-title":"GABAA receptor: positive and negative allosteric modulators","volume":"136","author":"Olsen","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2008.07.045","article-title":"GABAA receptors: subtypes provide diversity of function and pharmacology","volume":"56","author":"Olsen","year":"2009","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib131","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1152\/jn.2001.86.2.596","article-title":"Paradoxical reduction of synaptic inhibition by vigabatrin","volume":"86","author":"Overstreet","year":"2001","journal-title":"J. Neurophysiol."},{"issue":"9","key":"10.1016\/j.neuropharm.2020.107966_bib132","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/jhg.2013.77","article-title":"The SCN1A gene variants and epileptic encephalopathies","volume":"58","author":"Parihar","year":"2013","journal-title":"J. Hum. Genet."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.107966_bib133","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1157.1999.tb00832.x","article-title":"The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction","volume":"40","author":"Pisani","year":"1999","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2020.107966_bib134","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eplepsyres.2012.03.010","article-title":"Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials","volume":"101","author":"Porter","year":"2012","journal-title":"Epilepsy Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib135","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0896-6273(00)81203-9","article-title":"Selective depression of low-release probability excitatory synapses by sodium channel blockers","volume":"26","author":"Prakriya","year":"2000","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib136","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1528-1167.2006.00497.x","article-title":"Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA receptor channels","volume":"47","author":"Quilichini","year":"2006","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib137","first-page":"756","article-title":"Frequency and voltage-dependent inhibition of type IIA Na+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs","volume":"40","author":"Ragsdale","year":"1991","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib138","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1586\/ecp.12.74","article-title":"Polypharmacology: drug discovery for the future","volume":"6","author":"Reddy","year":"2013","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib139","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.neuron.2018.05.018","article-title":"Glutamatergic signaling in the central nervous system: ionotropic and metabotropic receptors in concert","volume":"98","author":"Reiner","year":"2018","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib140","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/106002809603000515","article-title":"Acetazolamide in the treatment of seizures","volume":"30","author":"Reiss","year":"1996","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib141","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.410350216","article-title":"Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and \u03b3-aminobutyric acid A receptors","volume":"35","author":"Rho","year":"1994","journal-title":"Ann. Neurol."},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2020.107966_bib142","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1113\/jphysiol.1996.sp021784","article-title":"Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons","volume":"497","author":"Rho","year":"1996","journal-title":"J. Physiol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib143","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0022-3565(24)36535-8","article-title":"Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate","volume":"280","author":"Rho","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib144","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/(SICI)1096-9861(19960415)367:4<595::AID-CNE9>3.0.CO;2-#","article-title":"GABA plasma membrane transporters, GAT-1 and GAT-3, display different distributions in the rat hippocampus","volume":"367","author":"Ribak","year":"1996","journal-title":"J. Comp. Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.107966_bib145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents","volume":"136","author":"Rigo","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(01)00116-4","article-title":"KCNQ potassium channels: physiology, pathophysiology, and pharmacology","volume":"90","author":"Robbins","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.107966_bib147","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ane.12099","article-title":"AMPA receptors as a molecular target in epilepsy therapy","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.neuropharm.2020.107966_bib148","first-page":"106506","article-title":"Reduced efficacy and risk of seizure aggravation when cannabidiol is used without clobazam","author":"Rogawski","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2020.107966_bib149","series-title":"Wyllie's Treatment of Epilepsy: Principles and Practice","article-title":"Mechanisms of action of antiseizure medications","author":"Rogawski","year":"2020"},{"key":"10.1016\/j.neuropharm.2020.107966_bib150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol. Scand. Suppl."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.107966_bib151","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm1074","article-title":"The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions","volume":"10","author":"Rogawski","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2020.107966_bib152","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res."},{"issue":"16","key":"10.1016\/j.neuropharm.2020.107966_bib153","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00018-007-7079-x","article-title":"The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?","volume":"64","author":"Rosenberg","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2020.107966_bib154","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-94-007-7359-2_14","article-title":"Carbonic anhydrases and brain pH in the control of neuronal excitability","volume":"75","author":"Ruusuvuori","year":"2014","journal-title":"Subcell. Biochem."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.107966_bib155","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2020.107966_bib156","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib157","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0014-2999(77)90270-9","article-title":"Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of \u03b3-acetylenic GABA and \u03b3-vinyl GABA, two irreversible GABA-T inhibitors","volume":"45","author":"Schechter","year":"1977","journal-title":"Eur. J. Pharmacol."},{"issue":"20","key":"10.1016\/j.neuropharm.2020.107966_bib158","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1523\/JNEUROSCI.0128-05.2005","article-title":"Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine","volume":"25","author":"Schenzer","year":"2005","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib159","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4155\/fmc.10.288","article-title":"GABA transport inhibitors and seizure protection: the past and future","volume":"3","author":"Schousboe","year":"2011","journal-title":"Future Med. Chem."},{"issue":"20","key":"10.1016\/j.neuropharm.2020.107966_bib161","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"CLN2 Study Group. Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib162","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1528-1157.1989.tb05300.x","article-title":"Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers","volume":"30","author":"Schwarz","year":"1989","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib163","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1152\/jn.1997.77.6.3021","article-title":"Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin","volume":"77","author":"Segal","year":"1997","journal-title":"J. Neurophysiol."},{"issue":"15 Suppl. ment","key":"10.1016\/j.neuropharm.2020.107966_bib164","article-title":"Effects of cenobamate on GABA-A receptor modulation","volume":"92","author":"Sharma","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0031-6997(25)06840-1","article-title":"Structure and pharmacology of \u03b3-aminobutyric acid A receptor subtypes","volume":"47","author":"Sieghart","year":"1995","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.neuropharm.2020.107966_bib166","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0165-6147(97)01118-8","article-title":"The benzodiazepine binding site of GABAA receptors","volume":"18","author":"Sigel","year":"1997","journal-title":"Trends Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.107966_bib167","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","article-title":"The benzodiazepine binding sites of GABAA receptors","volume":"39","author":"Sigel","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2020.107966_bib168","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1111\/j.1528-1157.2000.tb06046.x","article-title":"Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt","volume":"41","author":"Sills","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2020.107966_bib169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-642-41588-3_3","article-title":"Slow inactivation of Na+ channels","volume":"221","author":"Silva","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2020.107966_bib170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejphar.2006.09.002","article-title":"Felbamate is a subunit selective modulator of recombinant \u03b3-aminobutyric acid type A receptors expressed in Xenopus oocytes","volume":"552","author":"Simeone","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.107966_bib171","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.neuropharm.2005.12.006","article-title":"Subunit selectivity of topiramate modulation of heteromeric GABAA receptors","volume":"50","author":"Simeone","year":"2006","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib172","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.phrs.2011.03.004","article-title":"Topiramate modulation of \u03b21- and \u03b23-homomeric GABAA receptors","volume":"64","author":"Simeone","year":"2011","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib173","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1535-7511.2007.00156.x","article-title":"Persistent sodium current and its role in epilepsy","volume":"7","author":"Stafstrom","year":"2007","journal-title":"Epilepsy Curr."},{"issue":"5226","key":"10.1016\/j.neuropharm.2020.107966_bib174","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1126\/science.7638623","article-title":"Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors","volume":"269","author":"Staley","year":"1995","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0022-3565(25)12797-3","article-title":"Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons","volume":"277","author":"Stefani","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.107966_bib176","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1528-1157.1995.tb00958.x","article-title":"Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents","volume":"36","author":"Stefani","year":"1995","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib177","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1528-1167.2007.01001.x","article-title":"Carbamazepine and topiramate modulation of transient and persistent sodium currents studied in HEK293 cells expressing the Nav1.3 \u03b1-subunit","volume":"48","author":"Sun","year":"2007","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib178","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-1211(92)90087-A","article-title":"Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex","volume":"12","author":"Suzuki","year":"1992","journal-title":"Epilepsy Res."},{"issue":"18","key":"10.1016\/j.neuropharm.2020.107966_bib179","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1073\/pnas.86.18.7228","article-title":"T-type calcium channels mediate the transition between tonic and phasic firing in thalamic neurons","volume":"86","author":"Suzuki","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"10.1016\/j.neuropharm.2020.107966_bib180","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001","article-title":"Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine","volume":"21","author":"Tatulian","year":"2001","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib181","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/jm901524f","article-title":"The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors","volume":"53","author":"Temperini","year":"2010","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.107966_bib182","first-page":"761","article-title":"The alpha2-delta protein: an auxiliary subunit of voltage-dependent calcium channels as a recognized drug target","volume":"11","author":"Thorpe","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107966_bib183","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jmb.2004.09.048","article-title":"The three-dimensional structure of an ionotropic glutamate receptor reveals a dimer-of-dimers assembly","volume":"344","author":"Tichelaar","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib184","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/0006-8993(81)90828-3","article-title":"Effect of valproic acid on [3H]diazepam and [3H]dihydropicrotoxinin binding sites at the benzodiazepine-GABA receptor-ionophore complex","volume":"223","author":"Ticku","year":"1981","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2020.107966_bib186","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.physiol.66.032102.113328","article-title":"Localization of voltage-gated ion channels in mammalian brain","volume":"66","author":"Trimmer","year":"2004","journal-title":"Annu. Rev. Physiol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107966_bib187","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ana.410250302","article-title":"Differential regulation of \u03b3-aminobutyric acid receptor channels by diazepam and phenobarbital","volume":"25","author":"Twyman","year":"1989","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib188","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/j.1552-4604.1984.tb01822.x","article-title":"A classification of antiarrhythmic actions reassessed after a decade of new drugs","volume":"24","author":"Vaughan Williams","year":"1984","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.107966_bib189","series-title":"The Treatment of Epilepsy","first-page":"75","article-title":"Mechanisms of antiepileptic drug action","author":"Walker","year":"2016"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(01)01243-2","article-title":"Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects","volume":"428","author":"Wallace","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"18","key":"10.1016\/j.neuropharm.2020.107966_bib191","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1097\/00001756-199611250-00048","article-title":"Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones","volume":"7","author":"Wang","year":"1996","journal-title":"Neuroreport"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib192","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/19336950.2017.1380758","article-title":"Distribution and function of voltage-gated sodium channels in the nervous system","volume":"11","author":"Wang","year":"2017","journal-title":"Channels"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107966_bib193","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/(SICI)1096-9861(20000619)422:1<123::AID-CNE8>3.0.CO;2-X","article-title":"Distribution of voltage-gated sodium channel alpha-subunit and beta-subunit mRNAs in human hippocampal formation, cortex, and cerebellum","volume":"422","author":"Whitaker","year":"2000","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107966_bib194","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib195","doi-asserted-by":"crossref","first-page":"e60314","DOI":"10.1371\/journal.pone.0060314","article-title":"GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.107966_bib196","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1152\/jn.00856.2002","article-title":"Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release","volume":"89","author":"Wu","year":"2003","journal-title":"J. Neurophysiol."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107966_bib197","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.neuron.2016.08.012","article-title":"Structural bases of noncompetitive inhibition of AMPA-subtype ionotropic glutamate receptors by antiepileptic Drugs","volume":"91","author":"Yelshanskaya","year":"2016","journal-title":"Neuron"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2020.107966_bib198","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","article-title":"Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate","volume":"41","author":"Zhang","year":"2000","journal-title":"Epilepsia"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820300320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820300320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:01:49Z","timestamp":1758438109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820300320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":197,"alternative-id":["S0028390820300320"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107966","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of action of currently used antiseizure drugs","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107966"}}